Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce W Robinson

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Current Opinion in Pulmonary Medicine|May 29, 2015
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesotheliomaJenette Creaney, Ian M Dick, Bruce W Robinson
Respirology (Carlton, Vic.)|April 22, 2016
Immunotherapy for lung cancerAntonius Steven, Scott A Fisher, Bruce W Robinson
Expert Review of Respiratory Medicine|January 1, 2019
Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicineLinda Ye, Shaokang Ma, Bruce W Robinson, et al.
Respirology (Carlton, Vic.)|March 31, 2015
Asbestos in AsiaSu Lyn Leong, Rizka Zainudin, Laurie Kazan-Allen, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2025
Neoantigen load as a predictor of relapse in early-stage NSCLC: features that agonise and antagonise prognosisLinda Ye, Ian Dick, Bruce W Robinson, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 2, 2016
Malignant pleural effusion: from bench to bedsideIoannis Psallidas, Ioannis Kalomenidis, Jose M Porcel, et al.
Translational Lung Cancer Research|December 10, 2025
Circulating stem-like exhausted CD8 T cells point to better outcomes in lung cancer: a brief reportLinda Ye, Ian Dick, Tina Firth, et al.
Plos One|September 23, 2014
Chemotherapy enhances cross-presentation of nuclear tumor antigensChidozie C Anyaegbu, Richard A Lake, Kathy Heel, et al.
Clinical & Developmental Immunology|May 22, 2012
Programmed death ligand 2 in cancer-induced immune suppressionEsdy N Rozali, Stanleyson V Hato, Bruce W Robinson, et al.
Nature Reviews. Clinical Oncology|November 1, 2023
Computational immunogenomic approaches to predict response to cancer immunotherapiesVenkateswar Addala, Felicity Newell, John V Pearson, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Current Opinion in Pulmonary Medicine|May 29, 2015
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesotheliomaJenette Creaney, Ian M Dick, Bruce W Robinson
Respirology (Carlton, Vic.)|April 22, 2016
Immunotherapy for lung cancerAntonius Steven, Scott A Fisher, Bruce W Robinson
Expert Review of Respiratory Medicine|January 1, 2019
Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicineLinda Ye, Shaokang Ma, Bruce W Robinson, et al.
Respirology (Carlton, Vic.)|March 31, 2015
Asbestos in AsiaSu Lyn Leong, Rizka Zainudin, Laurie Kazan-Allen, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2025
Neoantigen load as a predictor of relapse in early-stage NSCLC: features that agonise and antagonise prognosisLinda Ye, Ian Dick, Bruce W Robinson, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 2, 2016
Malignant pleural effusion: from bench to bedsideIoannis Psallidas, Ioannis Kalomenidis, Jose M Porcel, et al.
Translational Lung Cancer Research|December 10, 2025
Circulating stem-like exhausted CD8 T cells point to better outcomes in lung cancer: a brief reportLinda Ye, Ian Dick, Tina Firth, et al.
Plos One|September 23, 2014
Chemotherapy enhances cross-presentation of nuclear tumor antigensChidozie C Anyaegbu, Richard A Lake, Kathy Heel, et al.
Clinical & Developmental Immunology|May 22, 2012
Programmed death ligand 2 in cancer-induced immune suppressionEsdy N Rozali, Stanleyson V Hato, Bruce W Robinson, et al.
Nature Reviews. Clinical Oncology|November 1, 2023
Computational immunogenomic approaches to predict response to cancer immunotherapiesVenkateswar Addala, Felicity Newell, John V Pearson, et al.
Pageof 4